Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.

Zeidner JF. et al, (2025), Blood

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Turkalj S. et al, (2024)

Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Russell NH. et al, (2024), J Clin Oncol

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Supplementary Tables and Figures from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

Lachowiez CA. et al, (2024)

Genome-wide association studies of Down syndrome associated congenital heart defects

Feldman ER. et al, (2024)

Risk Stratification in Older Intensively Treated Patients With AML.

Versluis J. et al, (2024), J Clin Oncol

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Risueño A. et al, (2024), Leukemia Research, 140

HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms

Kumar P. et al, (2024)

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.

Freeman SD. et al, (2023), Blood, 142, 1697 - 1707

Changing treatment changing prognosis of mutations

Vyas P., (2023), Blood, 142, 1583 - 1585

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Daver NG. et al, (2023), J Clin Oncol

Load More